Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN 1 20 versus TRI MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN 1 20 versus TRI MILI.
MICROGESTIN 1/20 vs TRI-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
None Documented
None Documented
Norethindrone: 5.2-12.8 hours (mean ~8 hours); Ethinyl estradiol: 7-20 hours (mean ~13 hours); hepatic impairment prolongs.
Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment.
Renal: 40% as metabolites, 20% as glucuronide and sulfate conjugates; Fecal: 35%; Biliary: <5%.
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive